• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma.

作者信息

Schell F C, Yap H Y, Hortobagyi G N, Issell B, Esparza L

出版信息

Cancer Chemother Pharmacol. 1982;7(2-3):223-5. doi: 10.1007/BF00254555.

DOI:10.1007/BF00254555
PMID:7083463
Abstract
摘要

相似文献

1
Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma.VP16 - 213（依托泊苷）用于难治性转移性乳腺癌的II期研究。
Cancer Chemother Pharmacol. 1982;7(2-3):223-5. doi: 10.1007/BF00254555.
2
Adriamycin and VP16-213 combination treatment for breast cancer previously treated by the CMF regimen.
Cancer Chemother Pharmacol. 1982;7(2-3):231-3. doi: 10.1007/BF00254557.
3
VP16-213 and cyclophosphamide in advanced breast cancer. A phase II study.
Cancer Chemother Pharmacol. 1983;10(3):154-7. doi: 10.1007/BF00255751.
4
Mitomycin-C, VP16-213 combination as third line chemotherapy in advanced breast cancer.
Cancer Chemother Pharmacol. 1982;7(2-3):227-9. doi: 10.1007/BF00254556.
5
Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.依托泊苷治疗晚期或复发性子宫内膜癌的II期试验：一项妇科肿瘤学组研究
Cancer Treat Rep. 1982 Aug;66(8):1669-71.
6
Phase II study of etoposide in the treatment of esophageal carcinoma.
Cancer Treat Rep. 1983 Apr;67(4):397-8.
7
Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.依托泊苷用于难治性多发性骨髓瘤的II期评估：一项东南癌症研究组试验
Cancer Treat Rep. 1986 Jun;70(6):801-2.
8
Multicenter Phase II trial of etoposide in refractory small cell lung cancer.
Cancer Treat Rep. 1985 Jan;69(1):127-8.
9
Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.
Gynecol Oncol. 1978 Feb;6(1):7-9. doi: 10.1016/0090-8258(78)90002-1.
10
Phase II trial of etoposide in adenocarcinomas of the upper gastrointestinal tract.
Cancer Treat Rep. 1983 May;67(5):509-10.

引用本文的文献

1
Efficacy of oral Etoposide in pretreated metastatic breast cancer: a multicenter phase 2 study.口服依托泊苷治疗经治转移性乳腺癌的疗效：一项多中心2期研究。
Medicine (Baltimore). 2015 May;94(17):e774. doi: 10.1097/MD.0000000000000774.
2
Chronic oral etoposide in advanced breast cancer.晚期乳腺癌的慢性口服依托泊苷治疗
Cancer Chemother Pharmacol. 1994;33(6):527-9. doi: 10.1007/BF00686513.
3
Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer.

本文引用的文献

1
Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer.长春花碱以连续5天输注的方式用于治疗难治性晚期乳腺癌。
Cancer Treat Rep. 1980 Feb-Mar;64(2-3):279-83.
2
Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors.
Eur J Cancer (1965). 1973 Mar;9(3):215-21. doi: 10.1016/s0014-2964(73)80021-0.
3
The chemical therapy of breast cancer.乳腺癌的化学疗法。
Semin Oncol. 1974 Jun;1(2):131-44.
Breast Cancer Res Treat. 1995 May;34(2):185-9. doi: 10.1007/BF00665790.
4
Hypersensitivity reactions from antineoplastic agents.抗肿瘤药物引起的超敏反应。
Cancer Metastasis Rev. 1987;6(3):413-32. doi: 10.1007/BF00144273.
5
Phase II study with etoposide in previously untreated advanced breast cancer.
Cancer Chemother Pharmacol. 1989;24(4):261-3. doi: 10.1007/BF00257630.
6
Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.依托泊苷。对其药效学和药代动力学特性以及在癌症联合化疗中的治疗潜力的综述。
Drugs. 1990 Mar;39(3):438-90. doi: 10.2165/00003495-199039030-00008.
7
Phase I-II study of high-dose etoposide in patients with refractory breast cancer.
Invest New Drugs. 1991 Nov;9(4):365-7. doi: 10.1007/BF00183583.
4
Combination chemotherapy for advanced breast cancer: response and effect on survival.
Ann Intern Med. 1976 Apr;84(4):389-92. doi: 10.7326/0003-4819-84-4-389.
5
Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer.
Cancer. 1975 Jul;36(1):90-7. doi: 10.1002/1097-0142(197507)36:1<90::aid-cncr2820360104>3.0.co;2-h.
6
Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.阿霉素加长春新碱与环磷酰胺、甲氨蝶呤和5-氟尿嘧啶联合用于晚期乳腺癌的比较及联合应用。
Cancer. 1975 Apr;35(4):1108-15. doi: 10.1002/1097-0142(197504)35:4<1108::aid-cncr2820350414>3.0.co;2-z.
7
Mitomycin-C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy.
Cancer. 1978 Feb;41(2):392-5. doi: 10.1002/1097-0142(197802)41:2<392::aid-cncr2820410202>3.0.co;2-7.
8
Chemo immunotherapy of advanced breast cancer with BCG.
Recent Results Cancer Res. 1977(62):143-50. doi: 10.1007/978-3-642-81174-6_21.
9
Etoposide (VP-16-213).
Cancer Treat Rev. 1979 Jun;6(2):107-24. doi: 10.1016/s0305-7372(79)80045-6.
10
Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer.
Cancer Treat Rep. 1979 Jan;63(1):77-83.